Evaluation of Anticancer Potency of Cu-Isatin-1-(2-Pyridylpiperazine) Thiosemicarbazone (Cu-Istpypz) Against Epidermoid Carcinoma Cell Line (A431)
Isatin
Semicarbazone
Epidermoid carcinoma
DOI:
10.2139/ssrn.4925558
Publication Date:
2024-08-19T15:50:28Z
AUTHORS (5)
ABSTRACT
A series of Isatin thiosemicarbazones and their copper(II) complexes were synthesized and evaluated for their anti-cancer activities to develop potent chemotherapeutic agents. Among the compounds synthesized, copper conjugated isatin-thiosemicarbazone derivative, Cu-Istpypz, showed considerable anti-proliferative activity against A431 (Skin Cancer) and A549 (Lung Cancer) cell lines. Cell viability assay using crystal violet dye exhibited the effects of the compounds against those cell lines. Cu-Istpypz was highly effective in inhibiting A431 cell proliferation at lower concentrations. The compound Cu-Istpypz also suppressed the colony formation of A431 cells in a concentration-dependent manner, as demonstrated by the clonogenic assay. Additionally, at higher concentrations, Cu-Istpypz slowed down the migration and wound-healing capabilities of A431 cells. RT-PCR and western blot analysis indicated that the compound induced the expression of pro-apoptotic Bax and inhibited anti-apoptotic Bcl-2 and Bcl-xl in a concentration-dependent manner. Further, the compound induces intrinsic apoptosis in A431 cells by activating the JNK signalling pathway and suppressing the PI3K/AKT pathway. DNA fragmentation assay further confirms the onset of apoptosis in the presence of the compound. All these confirm that Cu-Istpypz thiosemicarbazone has the potential to be developed as a future chemotherapeutic agent in the treatment of skin cancer.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....